Use of abciximab prevents microcirculatory impairment in patients treated with coronary angioplasty for unstable angina: Results of a prospective randomized study

Catheterization and Cardiovascular Interventions

Volumn 66, Issue 2, 2005, Pages 165-169

  Prati, Francesco ^a,b   Kwiatkowski, Piotr ^a   Caroselli, Constantino ^a   Imola, Fabrizio ^a   Manzoli, Alessandro ^a   Fouad, Tamer ^a   Corvo, Pierfrancesco ^a   Ramazzotti, Vito ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b European Imaging Laboratory   (Italy)

Author keywords

Angioplasty; Glycoprotein inhibitors; Microcirculation

Indexed keywords

ABCIXIMAB; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; TROPONIN I;

ADULT; AGED; ARTICLE; BLOOD VOLUME; CALCULATION; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEART PERFUSION; HEART VOLUME; HEMATOMA; HUMAN; IMMUNOTHERAPY; INGUINAL REGION; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; OPEN STUDY; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; VIDEORECORDING;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CREATINE KINASE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MICROCIRCULATION; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME;

EID: 26644453953     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20456     Document Type: Article

References (21)

1. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independed of gender. J Am Coll Cardiol 2000;36:381-386.
2. EPIC investigators. Use of a monoclonal antibody directed against platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
3. EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneus coronary revasculamation. N Engl J Med 1997;336:1689-1696.
4. EPISTENT investigators. Enhancement of the safety of coronary stenting with the use of abciximab, platelet glycoprotein IIb/IIIa inhibitor. Lancet 1998;352:87-92.
5. CAPTURE investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-1629.
6. Prati F, Pawlowski T, Gil R, et al. Stenting of culprit lesions in unstable angina leads to a marked reduction in plaque burden: a major role of plaque embolization? a serial intravascular ultrasound study. Circulation 2003;107:2320-2325.
7. Limbruno U, Micheli A, De Carlo M, et al. Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation 2003;108:171-176.
8. Wilson RF, Laxson DD, Lesser JR, White CW. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989;1:807-811.
9. Eeckhout E, Kem MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001;22:729-739.
10. Petronio AS, Rovai D, Musumeci G, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J 2003;24:67-76.
11. Braunwald E. Unstable angina: a classification. Circulation 1989; 80:410-414.
12. Prati F, Di Mario C, Moussa I, et al. In-stent neointimal proliferation correlates with the amount of residual plaque burden outside the stent: an intravascular ultrasound study. Circulation 1999;99:1011-1014.
13. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study). J Am Coll Cardiol 2002;40:1935-1942.
14. Destro G, Marino P, Carletti M, et al. Increased intensity of contrast material immediately after late angioplasty of infarct-related coronary artery is associated with reduced ventricular volumes at six months. Am J Cardiol 1998;82:1451-1456.
15. van't Hof AW, Aylee Liem, et al., on behalf of the Zwolle Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 1998;97:2302-2306.
16. Gibson CM, Cannon ChP, Murphy SA, et al., for the TIMI Thrombolysis In Myocardial Infarction Study Group. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-130.
17. van't Hof AW, Ernst N, de Boer MJ, de Winter R, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004; 25:837-846.
18. Costantini C, Stone GW, Mehran R, et al. Frequency, correlates and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J Am Coll Cardiol 2004;44:305-312.
19. Gibson CM, Cohen DJ, Cohen EA, et al. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Am J Cardiol 2001;87:1293-1295.
20. Dangas G, Mehran R, Feldman M, et al. Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention. Am J Cardiol 2002;89:586-589.
21. Ellis SG, Chew D, Chan A, et al. Death following creatinine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatinine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002;106:1205-1210.